Condition
Sinusitis
Sinusitis is inflammation of the sinuses, the air-filled spaces behind your forehead, cheeks and nose, and it can be short-term or last more than 12 weeks. Among supplements, N-acetyl cysteine and serrapeptase are the ones people look at most, since both may thin mucus and ease swelling. Little research on any of them has been reviewed here so far, so there are no findings to report yet, and the evidence looks moderate for N-acetyl cysteine and limited for serrapeptase.
- Supplements studied
- 2
- Graded outcomes
- 0
- Trials
- 2
- People studied
- 227
Evidence by supplement
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Mucus Production | Improves (the measure goes up) | 4 studies | 24 people | |||
Studies that measured mucus production
| ||||||
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Nasal Congestion | Improves (the measure goes up) | 1 study | 203 people | |||
Studies that measured nasal congestion | ||||||
The Sinusitis Support protocol
2 primary supplements · 4 supporting supplements
- Serrapeptase60,000–120,000 SPU daily on empty stomach
- N-Acetyl Cysteine (NAC)600–1,200 mg daily
Shop the evidence-backed picks
Fullscript collectionImmune support: evidence-graded picksOpen on Fullscript
The collection holds the supplements we grade A or B for its theme, in third-party tested products where the catalog has them. It opens in our Fullscript store. You can look through it without signing in; Fullscript asks for a free account to order.
We earn from purchases made in our Fullscript store, and links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Full disclosure
Studies cited
33 studies from PubMed
- The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial
- A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model
- A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling
- [Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-- a prospective study]
- Comparison of the roles of serratiopeptidase and dexamethasone in the control of inflammation and trismus following impacted third molar surgery
- Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo
- [Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase]
- Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease
- A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome
- Effect of expectorants on relaxation behavior of sputum viscoelasticity in vivo
- The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus
- Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial
- EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial
- Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children
- Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis
- Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides
- EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis
- Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study
- Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial
- Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots
- Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis
- Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents
- Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials.
- Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial
- Can the Pelargonium sidoides root extract EPs® 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children
- Herbal Medicine for Cough: a Systematic Review and Meta-Analysis.
- Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD
- Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial
- The efficacy of Pelargonium sidoides in the treatment of upper respiratory tract infections in children with transient hypogammaglobulinemia of infancy
- Treatment of signs and symptoms of the common cold using EPs 7630 - results of a meta-analysis.
- Immune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: modulation of secretory IgA, IL-6 and IL-15
- Herbal Medicine in Children With Respiratory Tract Infection: Systematic Review and Meta-Analysis.
- Pelargonium sidoides extract for treating acute respiratory tract infections.